title: Interferon-β and Interferon-γ Are Weak Inhibitors of Ebola Virus in Cell-Based Assays.
abstract: Previous studies have demonstrated little efficacy of interferons (IFNs) in animal models of Ebola virus disease. However, these studies were limited to a small number of type I IFNs and, during the most recent outbreak of Ebola virus, questions regarding the suitability of the animal models to evaluate IFNs were raised. To address the potential that anti-Ebola virus activity was overlooked, type I and type II IFNs (α-2a, α-2b, -β, -γ, and -universal) were tested in a variety of cell types (Vero E6, Huh 7 cells, and human macrophages). IFNs are weak inhibitors of Ebola virus Makona in these cell lines.
authors.affiliation: Integrated Research Facility and.
authors.forename: Julie
authors.initials: J
authors.lastname: Dyall
authors.affiliation: Integrated Research Facility and.
authors.forename: Brit J
authors.initials: BJ
authors.lastname: Hart
authors.affiliation: Integrated Research Facility and.
authors.forename: Elena
authors.initials: E
authors.lastname: Postnikova
authors.affiliation: Integrated Research Facility and.
authors.forename: Yu
authors.initials: Y
authors.lastname: Cong
authors.affiliation: Integrated Research Facility and.
authors.forename: Huanying
authors.initials: H
authors.lastname: Zhou
authors.affiliation: Integrated Research Facility and.
authors.forename: Dawn M
authors.initials: DM
authors.lastname: Gerhardt
authors.affiliation: Integrated Research Facility and.
authors.forename: Denise
authors.initials: D
authors.lastname: Freeburger
authors.affiliation: Integrated Research Facility and.
authors.forename: Julia
authors.initials: J
authors.lastname: Michelotti
authors.affiliation: Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland.
authors.forename: Anna N
authors.initials: AN
authors.lastname: Honko
authors.affiliation: Integrated Research Facility and.
authors.forename: Lisa Evans
authors.initials: LE
authors.lastname: DeWald
authors.affiliation: Integrated Research Facility and.
authors.forename: Richard S
authors.initials: RS
authors.lastname: Bennett
authors.affiliation: Integrated Research Facility and.
authors.forename: Gene G
authors.initials: GG
authors.lastname: Olinger
authors.affiliation: Integrated Research Facility and.|Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland.
authors.forename: Peter B
authors.initials: PB
authors.lastname: Jahrling
authors.affiliation: Integrated Research Facility and.
authors.forename: Lisa E
authors.initials: LE
authors.lastname: Hensley
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002522:Chlorocebus aethiops; D004357:Drug Synergism; D029043:Ebolavirus / Q000187:drug effects*; D006801:Humans; D016899:Interferon-beta / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D014709:Vero Cells
chemical_list: D000998:Antiviral Agents; D016899:Interferon-beta; D007371:Interferon-gamma
keywords: Ebola virus; antiviral; interferon.